Compare Quest Diagnostics Inc (DGX) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs F5 Inc — how do they compare? Quest Diagnostics Inc trades at $237.63 (market cap $26.21B), while F5 Inc trades at $419.82 (market cap $23.44B). The key difference: Quest Diagnostics Inc and F5 Inc are close in size by market cap, and Quest Diagnostics Inc pays a 1.45% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| DGX | FFIV | |
|---|---|---|
Market Cap | $26.21B | $23.44B |
Sector | Health | Technology |
52-Week High | $238.50 | $431.26 |
52-Week Low | $173.49 | $223.99 |
Enterprise Value | $31.97B | $22.08B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
F5 (FFIV) stock trades at $417.70, up 1.88% with bullish technical signals and strong earnings beats. Recent Q3 2026 results showed EPS of $4.73 versus $4.00 expected, driven by 19% product revenue growth. The company raised its fiscal outlook, reflecting robust demand for application security and AI infrastructure. Key support lies at $411, with resistance at $422.
Outlook remains positive due to consistent earnings outperformance and raised guidance, though valuation multiples like P/E of 32.98 suggest premium pricing. Risks include competitive pressures and reliance on enterprise spending cycles. Analyst consensus price target of $430.43 implies moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
